BYDFi Launches DOLO/USDT and INIT/USDT with a $10,000 Prize Pool
$DOLO: A Core Asset in the Berachain Ecosystem
$DOLO is the native token of the Dolomite protocol, serving key functions in governance, liquidity incentives, and risk hedging. Dolomite is a decentralized finance (DeFi) platform built on Berachain that integrates a DEX module, enabling users to stake, lend, vote, and earn yield — all while maintaining full control of their assets, even when borrowing.
Since its inception in 2018, Dolomite has become one of Berachain's leading lending protocols, known for its virtual liquidity model, multi-layered reward system, and cross-protocol compatibility. Its co-founder, Corey Caplan, now serves as the Head of Technical Strategy for the Trump-affiliated DeFi initiative World Liberty Financial (WLFI), helping evolve Dolomite's technical framework. The project has raised over $3.4 million from prominent investors, including Coinbase Ventures, NGC Ventures, and Polygon.
$INIT: A Modular Layer 1 Built for the Future
Initia ($INIT) is a modular Layer 1 blockchain powered by the Omnitia Consensus mechanism and built using the Initia Interwoven Stack. It is designed to overcome scalability limitations in traditional blockchains and enable seamless cross-chain interoperability and resource sharing. With innovations like Gas Abstraction and a dual-deflationary token model, Initia enhances overall performance and security while significantly lowering the user barrier to cross-chain operations.
With innovations like Gas Abstraction and a dual-layer deflationary mechanism, INIT enhances performance, security, and cross-chain interoperability. Backed by leading VCs like Delphi Digital, Hack VC, and Theory Ventures, Initia has attracted over 5,000 developers, with a project valuation of $250 million.
Multiple Rewards Now Live on BYDFi
Starting today, users who trade DOLO/USDT and INIT/USDT on the BYDFi platform will not only have a chance to share in the $10,000 prize pool, but can also participate in the following limited-time bonus campaigns:
More details are available on BYDFi's official platform.
About BYDFi
Founded in 2020, BYDFi has been recognized by Forbes as one of the Top 10 Global Crypto Exchanges and is officially listed on CoinMarketCap and CoinGecko. Serving users in 190+ countries, the platform is trusted by over 1,000,000 users worldwide.
As an official sponsor of Token2049 in Dubai, BYDFi welcomes users and partners from around the world to connect in person and discuss the future of Web3. BYDFi is committed to delivering a world-class crypto trading experience for every user. BUIDL Your Dream Finance.
Twitter( X ) | LinkedIn | Facebook | Telegram | YouTube
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
3 hours ago
- Hamilton Spectator
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $30.54 per common share, which is equal to the closing price per share of Xenon's common shares on the grant date of July 31, 2025. The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee's start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient's continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company's 2025 Inducement Equity Incentive Plan. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit . 'Xenon' and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors: Chad Fugere Vice President, Investor Relations (857) 675-7275 investors@ For Media: Colleen Alabiso Senior Vice President, Corporate Affairs (617) 671-9238 media@
Hamilton Spectator
3 hours ago
- Hamilton Spectator
Lumine Group Inc. Announces Results for the Three and Six Months Ended June 30, 2025
TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) — Lumine Group Inc. ('Lumine Group' or 'the Company') (TSXV:LMN) announces financial results for the three and six months ended June 30, 2025. All amounts referred to in this press release are in US dollars unless otherwise stated. The following press release should be read in conjunction with the Company's unaudited condensed consolidated interim financial statements for the three and six months ended June 30, 2025, and management's discussion and analysis ('MD&A') for the three and six months ended June 30, 2025, which can be found on SEDAR+ at . Additional information about Lumine Group is also available on SEDAR+ and on Lumine Group's website . Q2 2025 Headlines: Year-to-Date Q2 2025 Headlines: Total revenue for the three months ended June 30, 2025 is $184.0 million, an increase of 13% or $21.1 million, compared to $162.8 million for the same period in 2024. For the six months ended June 30, 2025, total revenue was $362.6 million, an increase of 19%, or $58.7 million, compared to $303.9 million for the same period in 2024. The increase for the three and six months compared to the same period in the prior year is attributable to revenues from new acquisitions. The Company experienced organic growth of 9% and 2%, respectively, for the three and six months ended June 30, 2025, or 6% and 1% after adjusting for the impact of changes in the valuation of the US dollar against most major currencies in which the Company transacts business. For acquired companies, organic growth is calculated as the difference between actual revenues achieved by each business in the financial period following acquisition, compared to the estimated revenues they achieved in the corresponding financial period preceding the date of acquisition by the Company. Organic growth is not a standardized financial measure and might not be comparable to measures disclosed by other issuers. Operating income for the three months ended June 30, 2025 was $62.7 million, an increase of 71%, or $26.1 million, compared to $36.6 million for the same period in 2024. Operating income for the six months ended June 30, 2025 was $122.2 million, an increase of 51%, or $41.1 million, compared to $81.1 million for the same period in 2024. The increase for the three and six month periods is primarily attributable to growth from acquisitions. Operating income is not a standardized financial measure and might not be comparable to measures disclosed by other issuers. See 'Non-IFRS Measures'. Net income for the three months ended June 30, 2025 was $23.6 million compared to net loss of $2.2 million for the same period in 2024. Net income for the six months ended June 30, 2025 was $44.3 million compared to net loss of $306.6 million for the same period in 2024. The increase in net income for the three and six months is primarily attributable to growth from acquisitions and the Mandatory Conversion of Preferred and Special Securities on March 25, 2024 such that no further preferred and special securities expense was booked in the subsequent quarters. For the three months ended June 30, 2025, CFO increased $68.7 million to $78.4 million compared to $9.7 million for the same period in 2024 representing an increase of 705%. For the six months ended June 30, 2025, CFO increased $73.8 million to $118.5 million compared to $44.7 million for the same period in 2024 representing an increase of 165%. The primary reason for the increase is that CFO includes the impact of changes in non-cash operating assets and liabilities exclusive of effects of business combinations or changes in non-cash operating working capital ('NCOWC') which improved during the three and six months ended June 30, 2025 compared to the same period prior year, as well as higher operating income. For the three months ended June 30, 2025, FCFA2S increased $69.6 million to $72.4 million compared to $2.8 million for the same period in 2024. For the six months ended June 30, 2025, FCFA2S increased $75.8 million to $107.4 million compared to $31.5 million for the same period in 2024. The increase in the three and six months ended June 30, 2025 is driven by higher CFO compared to the same periods in 2024. FCFA2S is a non-IFRS Measure. See 'Non-IFRS Measures'. Non-IFRS Measures Operating income (loss) refers to income (loss) before income taxes, amortization of intangible assets, redeemable Preferred and Special Share expense, gain on bargain purchase, and finance and other expenses (income). We believe that operating income is useful supplemental information as it provides an indication of the profitability of the Company related to its core operations. Operating income (loss) is not a recognized measure under IFRS and may not be comparable to similar financial measures disclosed by other issuers. Accordingly, readers are cautioned that operating income (loss) should not be construed as an alternative to net income (loss). The following table reconciles operating income to net income: Free cash flow available to shareholders ''FCFA2S'' refers to net cash flows from operating activities less interest paid on lease obligations, interest paid on bank debt, transaction costs on bank debt, repayments of lease obligations, interest, dividends and other proceeds received, and property and equipment purchased net of proceeds from disposal. The Company believes that FCFA2S is useful supplemental information as it provides an indication of the uncommitted cash flow that is available to shareholders if Lumine Group does not make any acquisitions, or investments, and does not repay any debts. While the Company could use the FCFA2S to pay dividends or repurchase shares, the Company's objective is to invest all of its FCFA2S in acquisitions which meet the Company's hurdle rate. FCFA2S is not a recognized measure under IFRS and may not be comparable to similar financial measures disclosed by other issuers. Accordingly, readers are cautioned that FCFA2S should not be construed as an alternative to net cash flows from operating activities. The following table reconciles FCFA2S to net cash flows from operating activities: Forward Looking Statements Certain statements herein may be 'forward looking' statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Lumine Group or the industry to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to vary significantly from the results discussed in the forward looking statements. These forward looking statements reflect current assumptions and expectations regarding future events and operating performance and are made as of the date hereof and Lumine Group assumes no obligation, except as required by law, to update any forward looking statements to reflect new events or circumstances. About Lumine Group Inc. Lumine Group acquires, strengthens, and grows, vertical market software businesses in the communications and media industry. Learn more at . For further information: David Nyland Chief Executive Officer Lumine Group investors@ +1-437-353-4910 Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Condensed Consolidated Interim Statements of Financial Position (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statements of Income (Loss) (In thousands of USD, except per share amounts. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statements of Comprehensive Income (Loss) (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statement of Changes in Equity (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statement of Changes in Equity (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statements of Cash Flows (In thousands of USD. Due to rounding, numbers presented may not foot.) 1 See 'Non-IFRS Measures'.
Yahoo
4 hours ago
- Yahoo
Ethena's USDe Outpaces BlackRock's Bitcoin, Ether ETFs With $3.1B Inflow Surge
Ethena's synthetic stablecoin, USDe, has crossed $8.4 billion in supply, adding more than $3.14 billion over 20 days in a surge that outpaced flows into BlackRock's (BLK) flagship bitcoin and ether exchange-traded funds. According to on-chain data curated by the Ethena community, the supply increase since July 17 is the fastest period of growth since the protocol's inception in February 2024. Inflow into the yield-bearing stablecoin exceeds the $2.75 billion added to BlackRock's ether ETF (ETHA) and the $1.60 billion into its bitcoin ETF (IBIT) in the same period, making the DeFi-native stablecoin the biggest magnet for capital across both on- and off-chain markets in recent weeks. The rally has spilled over into Ethena's governance token ENA, which more than doubled in the past month, though it is down 12% in the past 24 hours as traders hope the long-awaited fee switch will soon activate. The protocol has already surpassed most of the thresholds required to distribute revenue to staked ENA holders, with the final benchmark, a favorable yield spread versus rivals, expected to be met soon. USDe's reflexive loop USDe's recent growth reflects a powerful reflexive loop built into its core design, as Nansen explained in a recent research report on the Ethena ecosystem. As bitcoin and ether prices rally, perpetual funding rates in turn increasingly positive. Ethena captures this funding via delta-neutral hedges, and distributes it as real-time yield to sUSDe holders. That higher yield then draws in more users, leading to greater USDe issuance, more hedging, and more protocol revenue. In the last month, Ethena has brought in nearly $50 million in feed and $10 million in revenue, according to DeFiLlama data. This makes it the sixth best-performing protocol for monthly fee revenue according to the data aggregator. ENA is currently trading for $0.58.
